-
July 10, 2024Umecrine Cognition raises MSEK 28.3 for the ongoing clinical development of golexanoloneSTOCKHOLM – July 10, 2024. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 28,3 million...
-
June 28, 2024Umecrine Cognition publishes new nonclinical data for golexanolone in Parkinson’s disease that will be presented at the FENS Forum 2024STOCKHOLM – June 28, 2024. Umecrine Cognition today announces that the company has published new nonclinical data in the journal Frontiers in Aging...
-
June 3, 2024Umecrine Cognition attends BIO 2024 in San DiegoSTOCKHOLM – June 3, 2024. Umecrine Cognition today announces that the company will attend the BIO International Convention in San Diego, USA. The...
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.